Skip to main content

Dr. William A. Pearce, M.D.

Ophthalmology (Ophthalmology Physician)

  • Medicare participating

At a glance

Years since graduation
14
In the NPI registry since
2012
Medicare patients seen, 2024
685

Licensed in Texas since 2021, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2012Medical school: University of Texas Medical Branch at Galveston
  • 2012Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Ophthalmology Physician primary
    TX license T1514 (first issued 2021; active) · TX license BP10042832

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Ophthalmology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
685
Services billed
12,408
Patients’ average age
76
Most frequent Medicare services, 2023
ServiceTimesPatients
Imaging of retina1,181455
Injection, aflibercept, 1 mg90096
Established patient complete exam of visual system603318
Injection of drug into eye570129
Injection, ranibizumab, 0.1 mg29514
New patient complete exam of visual system159159
New patient office or other outpatient visit, 45-59 minutes9191
Photography of the retina8679
Extended exam of the back part of the eye with retinal drawing4134
Exam of retinal blood vessels using a special camera after injection of a dye4040

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 5 companies reported 20 payments worth $679 in total to this clinician.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $669,960 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
    Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914
  • Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
    Ocular Therapeutix, Inc.
  • A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC …
    Boehringer Ingelheim Pharmaceuticals, Inc.
  • A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
    Boehringer Ingelheim International GmbH
  • JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
    Boehringer Ingelheim International GmbH

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Ophthalmology clinicians in Beaumont

Sources

NPI registry (CMS NPPES, November 2026; record last updated November 9, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1831457555. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.